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Background: The trigeminal subnuclei interpolaris/caudalis transition zones (Vi/Vc) play an important role in
orofacial deep pain, however, the role of primary afferent projections to the Vi/Vc remains to be determined. This
study investigated the functional significance of hyperalgesia to the brain-derived neurotrophic factor (BDNF)-
tyrosine kinase B (trkB) signaling system in trigeminal ganglion (TRG) neurons projecting to the Vi/Vc transition zone
following masseter muscle (MM) inflammation.
Results: The escape threshold from mechanical stimulation applied to skin above the inflamed MM was
significantly lower than in naïve rats. Fluorogold (FG) labeling was used to identify the TRG neurons innervating the
MM, while microbeads (MB) were used to label neurons projecting to the Vi/Vc region. FG/MB-labeled TRG neurons
were immunoreactive (IR) for BDNF and trkB. The mean number of BDNF/trkB-IR small/medium-diameter TRG
neurons was significantly higher in inflamed rats than in naïve rats. In whole-cell current-clamp experiments, the
majority of dissociated small-diameter TRG neurons showed a depolarization response to BDNF that was associated
with spike discharge, and the concentration of BDNF that evoked a depolarizing response was significantly lower in
the inflamed rats. In addition, the relative number of BDNF-induced spikes during current injection was significantly
higher in inflamed rats. The BDNF-induced changes in TRG neuron excitability was abolished by tyrosine kinase
inhibitor, K252a.
Conclusion: The present study provided evidence that BDNF enhances the excitability of the small-diameter TRG
neurons projecting onto the Vi/Vc following MM inflammation. These findings suggest that ganglionic BDNF-trkB
signaling is a therapeutic target for the treatment of trigeminal inflammatory hyperalgesia.* Correspondence: m-takeda@tokyo.ndu.ac.jp
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Although it is well known that the spinal trigeminal
nucleus caudalis (SpVc) and the upper cervical spinal
dorsal horn (C1-2) are important relay stations for tri-
geminal nociceptive inputs from inflammation and in-
jury in superficial and deep tissues [1,2], it has also been
reported that the nociceptive inputs from receptors in
deep craniofacial tissues are relayed to the ventral trigemi-
nal subnucleus interpolaris/caudalis transition region
(Vi/Vc) through the trigeminal subnucleus caudalis/cervical
dorsal horn C2 (Vc/C2) junction region [3]. Recent studies
demonstrate that orofacial injury and noxious stimulation
of dental and craniofacial region activates a distinct region
in the Vi/Vc transition zones [4-6]. Indeed, the injection of
an N-methyl-D-aspartate (NMDA) receptor antagonist into
the Vi/Vc transition zone attenuates hyperalgesia after mas-
seter muscle (MM) inflammation [7]. Sugiyo et al. [5] dem-
onstrated that reciprocal connections between the ventral
Vi/Vc transition zone and rostral ventromedial medulla
(RVM) pathways play a critical role in facilitating orofacial
hyperalgesia. These findings suggest that the trigeminal
Vi/Vc transition zone plays an important role in deep tissue
pain processing, integrating nociceptive orofacial pain in-
puts and the development of persisting orofacial pain [6].
Since previous studies have demonstrated that non-
synaptically-released diffusible chemical messengers, such
as adenosine triphosphate (ATP), substance P (SP) and
glial-derived neurotrophic factor (GDNF), act via local
paracrine mechanisms in the sensory ganglia to contribute
to the development of inflammation-induced sensory ab-
normalities [8-12], it can be assumed that transganglionic
communication is one mechanism by which central
sensitization can be triggered, and that suppression of
ganglionic sensitization can effectively reduce the cen-
tral sensitization of secondary neurons [13,14]. Brain-
derived neurotrophic factor (BDNF) facilitates pain
transmission and contributes to the development of
hyperalgesia [15-18] via the postsynaptic tyrosine kin-
ase B (trkB) receptor to modulate nociceptive signaling
in the spinal dorsal horn. BDNF is normally expressed
in small- and medium-sized dorsal root ganglion
(DRG) and trigeminal ganglion (TRG) neurons [19-21],
and is localized to dense-core vesicles in axon termi-
nals in the SpVc region [22]. Recent studies report
upregulation of BDNF and trkB immunoreactivity (IR)
in TRG neurons after tooth pulp inflammation or
injury [23,24]. These findings suggest that local release
of BDNF from TRG neuronal somata and/or nerve
terminals may regulate the excitability of TRG neurons
projecting onto the Vi/Vc transition zone following
deep tissue inflammation and may contribute to the
development of hyperalgesia. Therefore, the present
study investigated the functional significance of the
BDNF-trkB signaling system in TRG neurons projectingto the Vi/Vc transition zone on trigeminal hyperalgesia
following MM inflammation.
Methods
All experiments were approved by the Animal Use and
Care Committee of Nippon Dental University and were
consistent with the ethical guidelines of the International
Association of the Study of Pain [25]. Each experiment was
performed such that the experimenter was blind to experi-
mental conditions. Every effort was made to minimize the
number of animals used and their suffering.
Induction of masseter muscle inflammation
The experiments were performed on 18 adult male Wistar
rats (110-150 g; naïve, n = 8; inflamed, n = 10). Each ani-
mal was anesthetized with sodium pentobarbital (45 mg/
kg, i.p.), and complete Freund’s adjuvant (CFA) (0.05 ml
1:1 oil/saline suspension; inflamed rats) or vehicle (0.05
ml, 0.9% NaCl, pH 7.2; naïve rats) was injected into the
left side of the MM, as described previously [26]. In some
experiments (n = 2), the CFA-induced inflammation was
verified with Evan’s blue dye (50 mg/ml, 1 ml/kg, i.v.) ex-
travasation. Postmortem examination of the injected MM
showed the accumulation of blue dye in the MM, indicat-
ing that the plasma protein extravasation was due to
localized inflammation [10].
Double labeling of TRG neurons innervating MM and/or
projecting to the Vi/Vc region
For electrophysiological and immunohistochemical stud-
ies, fluorogold (FG, Fluorochrome, Englewood, USA)
and fluorescent latex microbead (MB, Lumafluor, Na-
ples, FL) labeling methods [27] were used. Male Wistar
rats were anaesthetized with pentobarbital sodium (45
mg/kg, i.p.) before FG solution (0.5% in distilled water,
10 μl) was injected into the left MM using a Hamilton
syringe with a 31-gauge needle. The dorsal surface of the
medulla oblongata at the obex level was then surgically
exposed and MB (0.05 μl) was injected ipsilaterally into
the Vi/Vc region (obex +0.5 mm, lateral 0.5 mm, depth
0.5 mm) by pressure injection through a glass micropip-
ette (tip diameter of 30–50 μm) as described previously
[5,27-29]. After MB injection, the muscle and skin inci-
sions were sutured and the rats were allowed to recover.
The injection sites and spread of MB were verified by
histology.
Mechanical threshold for escape behavior
The mechanical threshold for escape behavior was deter-
mined as described in previous studies [12]. Briefly, two
days after the injection of CFA or vehicle into the MM,
hyperalgesia was assessed with calibrated von Frey fila-
ments (Semmes-Weinstein Monofilaments, North Coast
Medical, CA). To evaluate the escape threshold, a set of
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overlying the MM in an ascending series of trials. Each
von Frey stimulation was applied three times in each
series of trials. The escape threshold intensity was deter-
mined when the rat moved its head away from at least
one of three stimuli.
BDNF and trkB immunohistochemistry
Immunohistochemistry was used to determine whether
inflammation induces BDNF and trkB expression in the
trigeminal ganglia in both naïve (n = 3) and inflamed
(n = 3) rats. Two days after CFA or vehicle injection rats
were anesthetized (sodium pentobarbital; 50 mg/kg, in-
traperitoneal), and transcardially-perfused with 1% so-
dium nitrite in phosphate buffered saline (PBS; 50 ml)
followed by Zamboni fixative (4% paraformaldehyde,
15% picric acid in 0.1 M phosphate buffer). Tissue was
post-fixed for up to 2 hours. The left TRG was removed
and incubated, in sequence, in 4% (5 min × 3), 10% (1 h),
20% (2 h) and 30% (overnight) sucrose solution. Sections
were cut (10 μm) with a cryostat (Leica, Nussloch,
Germany) and mounted on silane-coated glass slides.
Every third section was used for immunohistochemistry
using a modification of the method previously described
[10], with twenty sections analyzed per ganglion. Briefly,
sections were incubated with sheep anti-BDNF(1:200,
Millipore, CA, USA) and rabbit anti-trkB (1:1000,
Millipore, CA, USA) for 24 h at 4°C, followed by Alexa
Fluor® 568 donkey anti-sheep IgG (1:1000, Molecular
Probes, Eugene, OR, USA) and Alexa Fluor® 647 goat
anti-rabbit IgG (1:1000, Molecular Probes, Eugene, OR,
USA), respectively. Labeled cryosections were rinsed in
0.01 M PBS, 5 min, and mounted with antifade medium
(Molecular Probes). Control sections were incubated with-
out the primary antibody.
The number of BDNF/trkB-IR TRG neurons was
counted in each section. Immunopositive staining was
compared with background staining by comparing least
intense staining to that with primary antibody omitted
[10]. In this study, we determine the fluorescence wave
lengths of both BDNF and trkB to prevent interference.
Digital images were collected and stored on a computer
and analyzed with Adobe Photoshop and a Leica Im-
aging Analysis Tool. Confocal images were generated
with a Leica TCS NT laser scanning microscope (Leica,
Germany).
Acute cell dissociation and whole cell patch-clamp
recording for TRG neurons
Patch-clamp recordings were conducted two days after
CFA or vehicle injection, on naïve (n = 5) and inflamed
rats (n = 7). Acute dissociation of TRG neurons was
performed as described previously [10]. Briefly, adult rats
were decapitated and the left TRG rapidly removed andincubated for 15–25 min at 37°C in modified Hank’s
balanced salt solution (130 mM NaCl, 5 mM KCl,
0.3 mM KH2PO4, 4 mM NaHCO3, 0.3 mM Na2HPO4,
5.6 mM glucose, 10 mM N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES), pH 7.3) containing
type XI collagenase (2 mg/ml; Sigma, St. Louis MO,
USA) and type II collagenase (2 mg/ml; Sigma).
Cells were dissociated by trituration with a fire-
polished Pasteur pipette and plated onto poly-L-lysine-
coated coverslips in 35 mm dishes. The plating medium
contained Leibovitz’s L-15 solution (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% newborn calf serum,
26 mM NaHCO3 and 30 mM glucose. Cells were
maintained in 5% CO2, 37°C and used for recording 2-8 h
after plating. After incubation, the coverslips were trans-
ferred to the recording chamber in a standard external
solution containing 155 mM NaCl, 3 mM KCl, 1 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES and 20 mM glucose,
pH 7.3. The recording chamber (0.5 ml) was mounted
onto an inverted microscope (Nikon, Tokyo, Japan)
equipped with phase contrast, a video camera and two
micromanipulators. The chamber was perfused under
gravity with a standard external solution at approximately
0.5 ml/min.
Whole cell recordings were conducted with the rapid
perforated-patch technique [10,27]. Fire-polished patch-
pipettes (2–5 MΩ) were filled with 120 mM potassium
methanesulphonate, 20 mM KCl, 7.5 mM HEPES and 2
mM EGTA (ethylene glycol-bis-β-aminoethyl ether N,N,
N’,N’-tetra-acetic acid), pH 7.3, containing amphotericin
B (100 μg/ml). Current-clamp recordings were conducted
with an Axopatch 200B amplifier (Molecular Devices,
Foster City, CA, USA). Signals were low-pass filtered at 1
or 5 kHz and digitized at 10 kHz. To evaluate changes in
cell membrane resistance associated with membrane poten-
tial during recordings in the current-clamp mode, negative
current pulses (50–600 pA, 250 ms, 0.2 Hz) were injected
through the patch pipette. Action potentials (overshoot of
action potential > 0 mV) were elicited by depolarizing
current pulses (10–500 pA, 10-70 pA steps, 200 ms). The
threshold for action potentials was determined and defined
as the minimum current required for eliciting a single
spike. The tetrodotoxin (TTX) 1 μM sensitivity for TRG
neurons was tested, with neurons defined as TTX-resistant
(TTX-R) if no changes of spike amplitude elicited by
threshold depolarizing current pulses were found in the
presence of TTX [30]. The action potential firing rates were
assessed by counting the number of action potentials elic-
ited by depolarizing pulses (2-times threshold currents).
Spike duration was determined as the duration of the first
spike at the level of half amplitude. Access resistance was
checked throughout the experiments, and no significant
changes found during experiments. All recordings were
performed at room temperature. Since spontaneous
Figure 1 Changes in the mechanical escape threshold after
induction of MM inflammation and hyperalgesia. Two days
after complete Freund’s adjuvant (CFA) or vehicle was injected into
the skin overlying the ipsilateral MM, mechanical stimulation using
von Frey filaments was applied to assess hyperalgesia in naïve and
inflamed rats. Data are the mean ± SEM (naïve, n = 8; inflamed,
n = 10). *P < 0.05.
Takeda et al. Molecular Pain 2013, 9:49 Page 4 of 12
http://www.molecularpain.com/content/9/1/49fluctuations in the membrane potential were less than 1
mV, a depolarizing response is defined as over 1 mV.
The threshold for BDNF response (changes in the
membrane potential) of each neurons tested was deter-
mined by minimum concentration of BDNF (1–100 ng/
ml). After confirmation of a BDNF responsive cell, the
tyrosine kinase inhibitor K252a was applied. In the
current-clamp mode, the membrane potential in most
cells recovered within 5–14 min.
Drug application
All drugs were stored at −20°C and stock solutions
dissolved in distilled water. Drugs were subsequently
dissolved in a standard external solution on the day of
the experiment. BDNF (1-100 ng/ml; Sigma-Aldrich, St.
Louis, MO, USA) and tyrosine kinase inhibitor K252a
(10 ng/ml; Sigma-Aldrich) were added to the perfusion
solution for a period of 30–60 sec.
Data analysis
Data were stored on a computer for off-line analysis
(pClamp 8.0, Molecular Devices). Values are expressed
as mean ± SEM. Statistical analyses were performed
using Student’s te-test and one-way repeated measures
analysis of variance (ANOVA) followed by the Tukey-
Kramer/Dunnett’s post hoc tests for the data. P < 0.05
was considered statistically significant.
Results
Induction of MM inflammation and mechanical
hyperalgesia
After CFA injection into the MM region, animals
showed behavioral hyperalgesia, determined by probing
the injected site (the left side) overlying orofacial skin
with von Frey filaments. In inflamed rats, the threshold
for escape from mechanical stimulation applied to the
skin above the MM was significantly reduced one and
two days after CFA injection (2 days; 46.9 ± 8.2 to 9.5 ±
3.5 g, P < 0.05; Figure 1).
Retrograde labeling of TRG neurons innervating MM and/
or projecting to the Vi/Vc region
Based on our previous immunohistochemical examina-
tions [44], TRG cell bodies were classified according to
size as small (<30 μm), medium (30–39 μm) or large
(>40 μm) in this study. Figure 2A shows schematic
drawing of double labeling of TRG neurons and an
example of FG/MB-labeled TRG neurons. In naïve rats,
two days after the FG injection into the MM, 19.5% of
TRG neurons (751/3850) innervating MM were retro-
gradely labeled by FG (Figures 2B-D), similarly to described
in our previous studies [27]. Approximately half of these
neurons were also labeled with the MB (44.1%, 331/751)
and projected onto the Vi/Vc region (Figures 2C, 2D),similarly to as described previously [7]. These neurons
ranged from small to medium in diameter (<39 μm).
Similarly, in inflamed rats, 20.0% of TRG neurons innervat-
ing MM were retrogradely labeled by FG (733/3669;
Figure 2E). Approximately half of these neurons ranged
from small to medium in diameter, were labeled with the
MB retrograde tracer (47.9%, 351/733), and projected onto
the Vi/Vc region (Figure 2F, 2G).
Inflammation increases BDNF expression in FG/MB
labeled TRG neurons
In both naïve and inflamed rats, the location of FG/MB-
labeled BDNF-IR neuronal soma corresponded with
those in the third branch of the trigeminal nerve [10,31].
Figures 3A-G shows a typical example of FG/MB labeled
BDNF-IR TRG neurons in naïve and inflamed rats. The
FG/MB-labeled and BDNF-IR TRG neurons were small-
medium in diameters in naïve rats (34.1%, 113/331) as
described previously [21]. The size frequency of distribu-
tion of FG-/MB-labeled/BDNF-IR TRG neurons is
shown in Figure 3I. The number of small-medium diam-
eter BDNF-expressing neurons in the FG/MB-labeled
TRG increased in the inflamed rat (72.9%: 256/351)
compared to the naïve rat. The number of FG/MB-la-
beled BDNF-IR neurons was significantly higher in in-
flamed rats than naïve (naïve vs inflamed: 4.2 ± 0.9/
section vs 8.5 ± 1.1/section, P < 0.01; Figure 3K). In the
absence of primary antibody only background staining
was evident (data not shown).
Figure 2 Schematic drawing of double labeling of TRG neurons
and an example of FG/MB-labeled TRG neurons. A: TRG neurons
innervating the masetter muscle (MM) were labeled by fluorogold
(FG) and the same neurons projecting to the trigeminal subnucleus
interpolaris/caudalis transition region (Vi/Vc) were labeled by
fluorescent latex microbeads (MB). Inset show the location of MB
injection sites. AP, area postrema; NTS nucleus of tractus solitaries;
Cu, cunate nucleus, LRN, Lateral reticular nucleus; Pyt, pyramidal
tract. B-C: TRG neurons that innervated masseter muscle (MM) (B)
projected onto the Vi/Vc region (C) in naïve rats. E-F: TRG neurons
that innervated masseter muscle (MM) (E) projected onto the Vi/Vc
region (F) in inflamed rats. B,E: Fluorescence micrograph showing
FG-labeled TRG neurons. C,F: MB-labeled TRG neurons in the same
section. D and G: Merge. Triangle shows an example of FG/MB-
labeled TRG neurons. Bar = 20 μm.
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TRG neurons
Similarly to the BDNF-IR TRG neurons, the location of
FG/MB-labeled trkB-IR neuronal soma corresponded
with those in the third branch of the trigeminal nerve.
Examples of FG-/MB-labeled trkB-IR TRG neurons in
naïve and inflamed rats are shown in Figures 3A, 3B, 3D
and Figures 3E, 3F, 3H, respectively. The FG/MB-labeled
and trkB-IR TRG neurons were small-medium in diame-
ters in naïve rats (31%, 101/331). Importantly, the major-
ity of FG/MB-labeled BDNF-IR neurons also expressed
trkB (naïve 86%; inflamed 93%). The size frequency of
distribution of FG-/MB-labeled/trkB-IR TRG neurons
is shown in Figure 3J. The number of small-medium
diameter trkB-expressing neurons in the FG-/MB-la-
beled TRG increased in the inflamed rat (66%: 226/351)compared to the naïve rat. The number of FG/MB-la-
beled trkB-IR neurons was significantly higher in in-
flamed rats than naïve rats (naïve vs inflamed: 4.6 ± 0.5/
section vs 8.9 ± 1.3/section, P < 0.01; Figure 3L). In the
absence of the primary antibody only background stain-
ing was evident (data not shown).
General electrophysiological properties of FG/MB-labeled
TRG neurons
Based on the upregulation of BDNF and trkB expression
in small-medium diameter TRG neurons after inflamma-
tion, and our interest in inflammatory hyperalgesia, we
used small-diameter TRG neurons for the electrophysio-
logical recordings. The isolated FG/MB-labeled TRG
neurons were spherical in shape and bright in appear-
ance with a ‘halo’ around the cell body when viewed by
phase contrast microscopy (Figures 4A-C). Figure 4D
shows the size distribution of recorded FG/MB-labeled
TRG neurons responding to 50 ng/ml BDNF (responding
cell; naïve 19/36, 53%; inflamed 31/37, 84%). Since previous
studies have suggested that BDNF may cause significant
changes in neuronal excitability of DRG neurons [32] and
Purkinje cells in the cerebellum [33], we used this concen-
tration to test BDNF responsiveness of TRG neurons. The
mean cell diameter of FG/MB-labeled TRG neurons used
for electrophysiological recordings in naïve and inflamed
rats was 26.5 ± 4.8 μm (n = 73). There was a tendency for
the BDNF responsiveness to be greater in inflamed rats
than in naïve rats. Following perforation of the cell mem-
brane with amphotericin B in dissociated TRG neurons
(naïve, n = 36; inflamed, n = 37), the series resistance
dropped to below 20 MΩ (17.1 ± 5.3 MΩ, n = 73) within
3–9 min and remained stable for over 15 min. The mean
cell capacitance was 15.2 ± 4.9 pF (n = 73).
Effect of BDNF on the resting membrane potential of
small-diameter FG/MB-labeled TRG neurons in naïve and
inflamed rats
To determine whether BDNF alters the excitability of
TRG neurons, the effect of BDNF on the resting mem-
brane potential of FG/MB-labeled small-diameter TRG
neurons in naïve and inflamed rats was examined. Since
BDNF depolarized the majority of neurons (naïve 14/19,
74%; inflamed 26/31, 84%) and the remaining neurons
were hyperpolarized after BDNF application (naïve 5/19,
27%; inflamed 5/31, 13%), in this study we focused on
the depolarization response.
Figure 5A shows a typical example of the depolarizing
response of FG/MB-labeled TRG neurons to BDNF (50
ng/ml) with associated decreasing input resistance, in
naïve rats. The duration of the depolarizing response
ranged from 4 to 8 min. Figure 5B shows a typical ex-
ample of a strong depolarization response to BDNF (10
ng/ml) which induced increments in spike discharge
Figure 3 Difference between expression of BDNF and trkB in TRG neurons in naïve and inflamed rats. A-D: Naïve rats. FG/MB-labeled TRG
neurons innervating MM (A) and projecting to Vi/Vc (B). Triangle shows an example of FG/MB-labeled and BDNF/trkB-IR TRG neurons. E-H:
Inflamed rats. FG/MB-labeled TRG neurons innervating MM (C,D) (E) and projecting to Vi/Vc (F). Triangle shows an example of FG/MB-labeled and
BDNF/trkB-IR TRG neurons. Bar = 20 μm. I: Size frequency distribution of FG/MB-labeled BDNF-IR TRG neurons in naïve and inflamed rats (G,H). K:
Comparison of FG/MB-labeled BDNF-IR TRG neurons per section in both naïve and inflamed rats. *P < 0.05. J: Size frequency distribution of FG/
MB-labeled trkB-IR TRG neurons in naïve and inflamed rats. L: Comparison of FG/MB-labeled trkB-IR TRG neurons per section in both naïve and
inflamed rats.*P < 0.05.
Takeda et al. Molecular Pain 2013, 9:49 Page 6 of 12
http://www.molecularpain.com/content/9/1/49frequency and was associated with a decrease in input
resistance in inflamed rat TRG neurons. The duration of
the BDNF-induced depolarizing response in inflamed
rats was significantly longer than in naïve rats (naïve vs
inflamed; 4.8 ± 2.2 min vs 8.6 ± 3.1 min, P < 0.05). Al-
though relatively few neurons (3/14, 21%) in naïve ratsshowed spontaneous discharges, there was a two-fold in-
crease in the number of TRG neurons (11/36, 42%) hav-
ing spontaneous discharges (Figure 5C) in the inflamed
rats, and the discharge rate was greater than in naïve
rats (naïve vs inflamed; 0.8 ± 0.4 Hz, n = 3, vs 2.6 ±
1.1 Hz, n = 11; P < 0.05), supporting previous findings
Figure 4 Double-labeling of dissociated TRG neurons recorded
under current-clamp and BDNF responsiveness in naïve and
inflamed rats. Acutely dissociated TRG neurons observed under
phase contrast microscopy (A), identified by FG-injection in the MM
(B) and by MB injection into the Vi/Vc region in the same field (C).
Bar = 20 μm. Arrow heads denote the target cell following FG/MB
injection. D: Size distribution of dissociated FG/MB-labeled small-
diameter TRG neurons recorded in both naïve and inflamed rats.
BDNF responsiveness was determined by changes in the membrane
potentials (>1 mV). E: Percentage of BDNF responsiveness in FG/MB-
labeled small-diameter TRG neurons.
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a depolarizing response in the inflamed rats was signifi-
cantly lower than in naïve (naïve vs inflamed; 52.3 ± 14
ng/ml vs 12.9 ± 6.3 ng/ml; P < 0.05; Figure 5D). This de-
polarizing response was associated with a decrease in
cell input resistance and this decreasing input resistance
was significantly higher in inflamed rats than in naïve
rats (naïve vs inflamed; 11.4 ± 2.3% vs 25.2 ± 5.5%; P <
0.05). BDNF-induced depolarization was significantly in-
creased in dose-dependent manner in both naïve and in-
flamed rats (1–100 ng/ml) and the mean depolarizationof FG/MB-labeled TRG neurons induced by BDNF in
inflamed rats was significantly higher than in naïve rats
(Figure 5E). The mean firing frequency of inflamed rat
FG/MB-labeled TRG neurons evoked by BDNF was sig-
nificantly higher than in naïve rats (Figure 5F). The mean
neuronal resting membrane potential in inflamed rats was
not significantly different to naïve rats (naïve vs inflamed; -
55.2 ± 2.9 mV, n = 16 vs −52.1 ± 2.3 mV, n =26; NS;
Figure 5F), as described in a previous study [30].
Effect of BDNF on the firing rate of small-diameter FG/
MB-labeled TRG neurons in naïve and inflamed rats
To determine whether MM inflammation alters spike gen-
eration evoked by BDNF in FG/MB-labeled small-diameter
TRG neurons, the changes in action potential firing rate in-
duced by a depolarizing step pulse was examined in the ab-
sence and presence of BDNF in naïve and inflamed rats.
Small-diameter FG/MB-labeled TRG neurons had several
characteristics typical of nociceptors: (1) small size (<30
μm); (2) presence of long-duration action potentials [34];
and (3) resistance of the action potential to TTX [35,36]. A
typical example of the wave form of an action potential is
shown in Figure 6A. In current-clamp mode, FG/MB-la-
beled small-diameter TRG neurons exhibited a long
duration (4.3-8.8 ms) with a prominent shoulder on the
repolarization phase (naïve, n = 7; inflamed, n = 10). All
neurons tested exhibited action potentials in the presence
of TTX (1 M; Figure 6B).
Figure 6C shows a typical example of the effect of
BDNF and co-application of K252a on the spike gener-
ation during depolarizing pulses in small-diameter FG/
MB-labeled TRG neurons in naïve and inflamed rats.
Similarly to a previous study [30], in the present study
we observed; (1) the threshold current of FG/MB-labeled
TRG neurons in inflamed rats was significantly decreased
compared to naïve rats (121.2 ± 12.4 pA vs 61.1 ± 8.9 pA;
P < 0.05; Figure 6C, upper trace and Figure 6D); (2) the
number of spike discharges during current injections by
FG/MB-labeled TRG neurons in inflamed rats was signifi-
cantly increased compared to naïve rats (1.2 ± 0.3 spikes vs
2.1 ± 0.2 spikes; P < 0.05; Figure 6C, upper trace and
Figure 6E). In both naïve and inflamed rats, the number of
spike discharges during the current injection significantly
increased after BDNF (50 ng/ml) application (n = 5, P <
0.05; Figure 6C middle trace and Figure 6E). The threshold
current of spike generation significantly decreased after
BDNF application in both naïve and inflamed rats (n = 5,
P < 0.05; Figure 6D). The relative number of spikes during
current injection (100 pA, 200 ms) was significantly
higher in inflamed rats than in naïve rats (355.2 ±
41.4% vs 205.3 ± 38.9%, respectively, n = 5, P < 0.05;
Figure 6F). The decreased threshold current evoked by
BDNF was blocked by co-administration of the tyro-
sine kinase inhibitor, K252a (10 ng/ml) in both naïve
Figure 5 Effect of BDNF on the neuronal excitability of small-diameter FG/MB-labeled TRG neurons in naïve and inflamed rats. A: BDNF
(50 ng/ml) induced neuronal depolarization with spike discharges in FG/MB labeled TRG neurons in naïve rats. The break in the trace is 5 min. B:
BDNF(10 ng/ml) induced strong neuronal depolarization with spike discharges in small-diameter FG/MB labeled TRG neurons in inflamed rats. The
break in the trace is 13 min. C: Spontaneous discharge in small-diameter FG/MB labeled TRG neurons in inflamed rats. The percentage and mean
firing frequency of TRG exhibiting spontaneous discharges increased following inflammation. The break in the trace is 7 min. D: The threshold
concentration of BDNF required for spike generation depolarization in inflamed rats was significantly lower than in naïve rats. E: Dose–response
relationship for BDNF-induced depolarization in naïve and inflamed rats. (n = 4, #, p < 0.05, 1 vs 10, 50 and 100 ng/ml, *, p < 0.05, naïve vs
inflamed). F: Comparison of discharge frequency induced by BDNF (50 ng/ml) in naïve and inflamed rats. *P < 0.05.
Takeda et al. Molecular Pain 2013, 9:49 Page 8 of 12
http://www.molecularpain.com/content/9/1/49and inflamed rats (Figure 6C, lower trace and
Figure 6D). Increased spike discharges evoked by
BDNF were also blocked by co-administration of
K252a (10 ng/ml) in both naïve and inflamed rats
(Figure 6C, lower trace and Figure 6E).
Discussion
Inflammation upregulates BDNF/trkB expression in TRG
neurons innervating MM and projecting to the Vi/Vc
By means of double-labeling tracing techniques with FG
and MB, we observed that approximately half of TRG
neurons identified masseteric input to ventral Vi/Vc
transition zone in this study. This was consistent with
the report that both masseter and cutaneous inputs to
project the Vc, masseter afferents provide an addtional
input to the Vi/Vc [37]. Since the location of deposits of
MB was localized in the Vi/Vc region (Figure 2), it is un-
likely that MB was taken up by damaged fibers thatcourse laterally through the region and that the tracer
spreads to the spinal trigeminal tract. Also, there was no
significant difference in the percentage of FG/MB-labeled
neurons between naïve and inflamed rats (P >0.05). Taken
together, therefore, our double-retrograde labeling methods
are a valid technique for examining the primary afferent
TRG neurons innervating MM and projecting to the Vi/Vc
region.
BDNF is expressed in small-medium diameter DRG neu-
rons that also express tyrosine kinase A (trkA) and calci-
tonin gene related peptide (CGRP). BDNF synthesized in
the DRG [19,38,39] was transported to the central termi-
nals of primary afferents [19,38,39] and released into the
spinal dorsal horn, where it bound to the trkB receptors on
the second order neurons to modulate painful stimuli
[40-42]. Similarly, small-medium diameter TRG neurons
also expressed both BDNF and trkB in naïve rats [21,43,44].
Furthermore, we found that most of FG/MB-labeled small-
Figure 6 Comparison of effect of BDNF on the firing frequency of small-diameter FG/MB-labeled TRG neurons from naïve and
inflamed rats. A: Wave form of action potential in response to depolarizing current pulses. Note the prominent shoulder on the falling phase
(triangle). B: Action potential induced at threshold level (300 ms, 100 pA) which was resistant to TTX (1 μM). C: Action potential firing rate during
depolarization of step pulse before (upper trace) and after (middle trace) BDNF (50 ng/ml), and after BDNF (50 ng/ml) + K252a (10 ng/ml; lower
trace) application to small-medium diameter TRG neurons in naïve and inflamed rats. D: Threshold current for spike generation during current
injection before and after BDNF and after BDNF + K252a applications; P < 0.05. E: Number of spike discharges during current injection before and
after BDNF and after BDNF + K252a applications; P < 0.05. F: The relative number of spikes during current injection (100 pA, 200 ms) was
significantly higher in inflamed rats than in naïve rats. *P < 0.05.
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trkB and that this expression was predominantly co-
localised (naïve 86%; inflamed 93%).
BDNF and trkB mRNA levels are reported to be signifi-
cantly increased in DRG neurons in a CFA inflammation
model [41,45,46]. BDNF and trkB in small-medium diam-
eter TRG neurons is known to be upregulated after inflam-
mation and tooth-injury, and BDNF is released from TRG
neurons in response to neuronal hyperactivity [22-24]. The
inflammation-induced upregulation of BDNF is hypothe-
sized to be mediated by NGF and hyperalgesia [41]. Periph-
eral inflammation and injury are also associated with the
release of pro-inflammatory cytokines such as tumor necro-
sis factorα (TNFα) and interleukin 1β (IL-1β) [47]. Recently,
Balkowiec-Iskra et al. [48] reported that TNFα upregulated
BDNF expression in TRG neurons via p38-mitogen-acti-
vated protein kinase (MAP) in an ‘NGF-independent man-
ner’, leading to trigeminal hyperalgesia. This study showsthat two days after CFA-induced MM inflammation, the
mean number of BDNF- and trkB-IR small-medium diam-
eter TRG neurons in inflamed rats was significantly higher
than in naïve rats. Therefore, taken together, these observa-
tions suggest that both NGF and cytokine signaling may
upregulate BDNF and trkB in small-medium diameter TRG
neurons to induce hyperalgesia. This is also supported by a
recent report that, under inflammatory conditions, en-
hanced production of BDNF in DRG neurons might
activate presynaptic trkB receptors via an autocrine/para-
crine signal to synergistically act with cytokines such as
TNFα, and upregulate synaptic excitability in pain trans-
mission [49].
Changes in the excitability of TRG neurons via
upregulation of BDNF and trkB
Although we have no evidence that release of BDNF
from TRG neurons into the TRGs is increased following
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that primary sensory neurons can release endogenous
BDNF in activity-dependent manner, and that the mag-
nitude of release dependents on the pattern and fre-
quency of stimulation [50,51]. Thus, it can be assumed
that TRG neurons contain BDNF secrete BDNF into the
extracellular space in the TRGs following neuronal exci-
tation, resulting in an increase in BDNF concentration
in the extracellular space.
Previous studies have indicated that BDNF is not only
a potent neuromodulator, but also has a fast excitatory
action on neurons which acutely controls resting
membrane potential, neuronal excitability and synaptic
transmission, and also participates in the induction of
synaptic plasticity [52]. With regards to the effect of
BDNF on nociceptive transmission, Matayoshi et al. [16]
reported that in spinal cord slice preparations, BDNF acted
on presynaptic terminals and increased the frequency of
miniature excitatory post-synaptic currents (mEPSCs) of
substantia gelatinosa neurons in CFA-induced inflamma-
tion via activation of receptor tyrosine kinase and TTX-
sensitive (TTX-s) Na+ channels. In addition, a previous
study demonstrated that acutely applied BDNF enhances
the excitability of dissociated small-diameter DRG neurons
via activation of the p75 neurotrophin receptor and its
downstream sphingomyelin signalling cascade and in-
creases in TTX-R Na+ currents [32].
In the present study, we observed that in inflamed
rats, the threshold for escape from mechanical stimula-
tion applied to the skin above the MM was significantly
reduced two days after CFA injection, suggesting inflam-
matory hyperalgesia. The present study demonstrated
that in dissociated FG/MB-labeled small-diameter TRG
neurons; (1) there was a tendency for the BDNF respon-
sive FG/MB-labeled small-diameter TRG neurons to be
larger in inflamed rats than naïve rats; (2) the threshold
concentration of BDNF that evoked a depolarizing re-
sponse of neurons in the inflamed rats was significantly
lower than in naïve rats; (3) BDNF induced higher fre-
quency and longer lasting spontaneous neuronal dis-
charges in inflamed rats; (4) The relative number of
BDNF-induced TTX-R neuronal spikes during current
injection was significantly higher in inflamed rats; (5)
The BDNF-induced changes in the TTX-R neuron excit-
ability was abolished by K252a. Thus, these findings
suggest that BDNF released from small-diameter TRG
neurons upregulates trkB through an paracrine/autocrine
mechanism, increasing spontaneous activity and triggering
the release of chemical neuromodulators (CGRP, SP and
ATP) which act on the neighboring neurons or satellite glial
cells via a similar mechanism [8-11,53].
BDNF binds to two structurally unrelated plasma
membrane receptor types, the p75 neurotrophin recep-
tor and the tyrosine kinase receptor trkB [54]. Activationof trkB by BDNF triggers intracellular signaling cascades
that effectively modulate voltage-gated, ligand-gated and
second-messenger gated ion channels [52,55]. Cao et al.
[8] report that paracrine released BDNF and trkB recep-
tor activation enhanced the excitability of DRG neurons in
diabetic neuropathy through voltage-gated A-type potas-
sium channels. In this study we observed that a BDNF-
induced depolarizing response was associated with a
decrease in cell input resistance. This decreased input re-
sistance in inflamed rats was significantly higher than in
naïve rats. The present study shows that BDNF-induced
depolarization and increased firing frequency in the TRG
neuron excitability was abolished by the tyrosine kinase in-
hibitor K252a. Since voltage-gated potassium channels de-
termine the resting membrane potential of neurons and
regulate their excitability [56], it can be speculated that
BDNF-induced increases in the excitability of FG/MB-la-
beled small-diameter TRG neurons may be due to the
depression of voltage-gated potassium currents. This is
supported by the following studies; (1) inhibition of
voltage-gated potassium currents by somatostatin,
interleukin 1β and GDNF in a small-diameter TRG
neurons potentiates neuronal excitability, thereby
contributing to trigeminal inflammatory hyperalgesia
[27,53,57]; (2) BDNF enhances the excitability of
small-diameter DRG neurons via activation of p75
neurotrophin receptor and suppression of delayed
rectifier-like potassium currents [38]. (3) BDNF signifi-
cantly affects auditory brainstem neuronal excitability
via a decrease in the potassium channels [58].
Although the precise ionic mechanism for BDNF-induced
enhanced TRG neuronal excitability is unclear, we hypothe-
sise that BDNF/trkB signaling induces hyperexcitability of
the small-diameter TRG neurons via a depression of
voltage-gated potassium currents within trigeminal ganglia.
Further studies are required to fully elucidate the under-
lying ion mechanisms between BDNF/trkB signaling and
TRG neuronal excitability, including other ion channels.Functional significance of BDNF/trkB signaling in the
trigeminal ganglia and inflammatory hyperalgesia
BDNF-trkB signaling within the RVM descending pathways
has been reported to contribute to the net descending fa-
cilitation of synaptic transmission in the Vi/Vc and pain
hypersensitivity [18,59]. In addition, inflamed MM primary
afferent inputs onto the Vi/Vc region are necessary and suf-
ficient to induce astroglial hyperactivity, concomitant IL-1β
induction, and coupling of neuronal NMDA receptor phos-
phorylation through IL-1β signaling [37]. Thus it can be
postulated that modulations of both synaptic transmission
in the Vi/Vc and the descending facilitation pathway from
the RVM are potential therapeutic targets for the treatment
of persisting orofacial pain.
Takeda et al. Molecular Pain 2013, 9:49 Page 11 of 12
http://www.molecularpain.com/content/9/1/49Several reports have demonstrated the functional
significance of transganglionic signal communication
[8-11,60-62], and we have previously suggested that
sensory signals are effectively amplified or attenuated
downstream of the ascending sensory pathway and
then sent to higher centers. Thus, transganglionic com-
munication, including neuron-satellite glial cell interaction,
is one mechanism by which central sensitization can be
triggered [53]. We recently provided evidence that in the
early stages of CFA inflammation, suppression of the SP/
neurokinin-1 receptor mechanism in trigeminal ganglia
may prevent central sensitization of hyperexcitability of
SpVc wide-dynamic range nociceptive neurons [14]. Taken
together, our reports suggest that blocking ganglionic
sensitization can effectively reduce the central sensitization
of nociceptive neurons and/or neuron-glial interactions in
the Vi/Vc transition zone. Therefore, in addition to BDNF/
trkB signaling in the central nervous system, the local para-
crine mechanism of BDNF/trkB on TRG neurons provides
a novel therapeutic target for the treatment of debilitating
orofacial deep inflammatory pain.
Conclusion
The present study provided evidence that BDNF en-
hances the excitability of the small-diameter TRG
neurons projecting onto the Vi/Vc following MM in-
flammation. These findings suggest that ganglionic
BDNF-trkB signaling is a therapeutic target for the
treatment of trigeminal inflammatory hyperalgesia.
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